Ulteriori informazioni
This book reviews the important new field of PET/CT-guided biopsy, which is of potential value in optimizing the diagnostic yield of biopsies. The role of this technology is examined in a range of malignancies, including lymphoma, pancreatic, breast cancer and CNS malignancies. True positive and false positive cases are presented and discussed, and many aspects of PET and pathology are addressed. The book describes many case presentations illustrated with mostly 18F-FDG PET/CT images, but also other PET radiopharmaceuticals such as 18F-FLT. The three editors are expert nuclear medicine physicians from Europe and North and South America, and the range of experiences gained in using PET/CT across the globe is reflected in the book.
Sommario
PART I. Biopsy guided PET/CT: Principle of biopsy guided imaging.- FDG PET/CT to guide biopsy: methods.- FDG PET/CT to guide biopsy: type of acess.- PART II. FDG PET/CT in lymphoma: Need of biopsy in lymphoma.- FDG PET/CT to guide biopsy in lymphoma: results.- PART III. FDG PET/CT in pancreatic lesions:Need of biopsy in pancreatic lesions.- FDG PET/CT to guide biopsy in pancreatic lesions: results.- PART IV. FDG PEM in breast lessions: Need of biopsy in breast lesions.- FDG PEM to guide biopsy in breast lesions: results.- PART V. PET/CT and CNS malignancies: Need of biopsy in CNS malignancies.- FDG PET/CT to guide biopsy in CNS: results.- PART VI. PET/CT and prostate cancer.- Choline PET/CT to guide biopsy in prostate cancer diagnosis.- PART VII. FLT PET/CT in cancer diagnosis: FLT PET/CT in cancer diagnosis: results.
Info autore
Juliano J. Cerci is the current head of PET/CT department of Quanta Diagnóstico e Terapia. Invited professor of Federal University of Paraná. After completing nuclear medicine training at Universisty of São Paulo, he pursued a radiology fellowship. He is currently vice-president of Brazilian Nuclear Medicine Society. The major focus of his career has been on oncological imaging and imaging-guided biopsy.
Stefano Fanti, is a Professor of Diagnostic Imaging at the University of Bologna and Director of Nuclear Medicine and PET Center at Policlinico S.Orsola in Bologna. The major focus of his career has been on PET imaging, with particular regards to oncology and innovative radiotracers.
Riassunto
This book reviews the important new field of PET/CT-guided biopsy, which is of potential value in optimizing the diagnostic yield of biopsies. The role of this technology is examined in a range of malignancies, including lymphoma, pancreatic, breast cancer and CNS malignancies. True positive and false positive cases are presented and discussed, and many aspects of PET and pathology are addressed. The book describes many case presentations illustrated with mostly 18F-FDG PET/CT images, but also other PET radiopharmaceuticals such as 18F-FLT. The three editors are expert nuclear medicine physicians from Europe and North and South America, and the range of experiences gained in using PET/CT across the globe is reflected in the book.
Testo aggiuntivo
“The interest of this agile publication is in supporting PET/CT as a guide to a better practice in biopsy. … this approach may be particularly useful in cases with complex lesions including necrosis and/or fibrosis, or in patients with multiple lesions, when a relapse is suspicious. In this sense, we suggest this book not only to nuclear physicians and radiologists involved in biopsy, but also to surgeons and oncologists interested in better understanding the possibilities of this new strategy.” (Valentina Piscopo and Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, 2017)
Relazione
"The interest of this agile publication is in supporting PET/CT as a guide to a better practice in biopsy. ... this approach may be particularly useful in cases with complex lesions including necrosis and/or fibrosis, or in patients with multiple lesions, when a relapse is suspicious. In this sense, we suggest this book not only to nuclear physicians and radiologists involved in biopsy, but also to surgeons and oncologists interested in better understanding the possibilities of this new strategy." (Valentina Piscopo and Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, 2017)
